Indegene Ltd (INDGN) is currently trading at 599.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Indegene Limited is a digital-first life sciences commercialization company, specializing in biopharmaceutical, biotech, and medical device sectors. It combines healthcare domain knowledge with technology to enhance product development and marketing. The company achieved a significant financial milestone in Q3 FY26 by surpassing $100 million in quarterly revenue for the first time, reflecting over 30% YoY growth. The successful execution of large AI-driven deals with global pharma leaders indicates Indegene's strategic focus on using Gen AI platforms to transform operations across commercial and medical sectors. Recent acquisitions of BioPharm and Warn & Co. have diversified and strengthened Indegene’s capabilities in omnichannel and consulting services, enhancing its market position. Despite challenges, Indegene maintains a robust financial position, with healthy cash reserves and strong cash generation, enabling sustained investment in growth and innovation.

Over the past 52 weeks, Indegene Ltd has traded between a low of ₹414.90 and a high of ₹616.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Indegene Ltd has a market capitalization of approximately 14,278.40. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Indegene Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 14,278.40 Cr, Indegene Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Indegene Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Indegene Ltd is 35.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Indegene reported consolidated net profit (PAT) of about ₹116 crore for the quarter ended June 30, 2026, which was flat year-on-year.

Indegene reported revenue of ₹9,421 million and net profit (PAT) of ₹1,029 million for the quarter ended December 31, 2025.